Celestra Inc, formerly Clinomics Inc, is a Korea-based company principally operates precision medical business based on genome-based healthcare and liquid biopsy platforms. The Company provides genome-based healthcare products and services that predict physical characteristics and diseases based on genome diagnosis and examination. The Company is engaged in the sale of medical devices and cancer diagnosis and monitoring that extract blood cells and deoxyribo nucleic acid (DNA) to diagnose patients. The Company is developing multi-omics-based early diagnosis service technology for diseases such as cancer.

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Korea S.E. Other stock markets 03/04/2025			5-day change	1st Jan Change
5,250.00 ^KRW	-20.63%		-0.00%	-0.00%

07/04/25	Celestra Inc. Auditor Raises 'Going Concern' Doubt	CI
18/03/25	Clinomics Inc. announced that it has received KRW 5.5 billion in funding	CI

Market Cap	13.41B 9.33M 8.11M 7.55M 6.93M 13.08M 890M 13.29M 88.96M 34.91M 443M 35.03M 34.26M 1.49B	P/E 2024	-0.4x	P/E 2025	-1.14x
Enterprise Value	17.19B 11.96M 10.4M 9.68M 8.89M 16.78M 1.14B 17.04M 114M 44.77M 568M 44.92M 43.93M 1.91B	EV / Sales 2024	5.8x	EV / Sales 2025	8.56x
Free-Float	78.31%	Yield 2024 *	-	Yield 2025	-

07/04/25	Celestra Inc. Auditor Raises 'Going Concern' Doubt	CI
18/03/25	Clinomics Inc. announced that it has received KRW 5.5 billion in funding	CI
13/03/25	Mirae Asset Securities Co., Ltd. agreed to acquire New Oriental Hotel Co., Ltd from Clinomics Inc. for KRW 14.5 billion.	CI
07/08/24	Clinomics Inc. announced that it expects to receive KRW 10 billion in funding	CI
17/05/24	Clinomics Inc. announced that it has received KRW 4 billion in funding	CI
14/05/24	Clinomics Inc. announced that it expects to receive KRW 4 billion in funding	CI
08/05/24	Clinomics Inc. announced that it has received KRW 32.600017466 billion in funding from Cdbio Co., Ltd., Daon Engineering Co., Ltd, Baro Savings Bank, The Korea Securities Finance Corporation	CI
03/05/24	Clinomics Inc. agreed to acquire New Oriental Hotel Co., Ltd from Daon Engineering Co., Ltd and Gi-dong Song for KRW 18.5 billion.	CI
21/03/24	Clinomics Inc. Auditor Raises 'Going Concern' Doubt	CI
15/12/23	Clinomics Inc. announced that it expects to receive KRW 15 billion in funding from Busan Equity Partners Co., Ltd.	CI
30/08/23	Tranche Update on Clinomics Inc.'s Equity Buyback Plan announced on August 30, 2023.	CI
30/08/23	Clinomics Inc. announces an Equity Buyback for 124,764 shares.	CI
30/08/23	Clinomics Inc.'s Equity Buyback announced on August 30, 2023, has closed with 124,764 shares, representing 0.61% for KRW 299.43 million.	CI

1 day	-20.63%
1 week	-0.00%
Current month	-0.00%
1 month	-0.00%
3 months	-0.00%
6 months	-0.00%
Current year	-0.00%

Celestra Inc. Stock

Stocks

A352770

KR7352770002

Biotechnology & Medical Research

Valuation: Celestra Inc.

Latest news : Celestra Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Celestra Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Income Statement and Estimates

Manager	Title	Age	Since
Seo-Hyeon Baek CEO	Chief Executive Officer	30	29/03/2024
Jong-Bin Baek AUD	Comptroller/Controller/Auditor	47	31/03/2025

Director	Title	Age	Since
Seo-Hyeon Baek BRD	Director/Board Member	30	29/03/2024
Hoo-Hyuk Hong BRD	Director/Board Member	42	25/09/2025
Young-Il Yoo BRD	Director/Board Member	41	14/06/2024

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CELESTRA INC.	-20.63%	-0.00%	-0.00%	-88.78%	9.33M
LONZA GROUP AG	-1.40%	+2.59%	-1.71%	+11.28%	48.53B
REVOLUTION MEDICINES, INC.	-2.41%	-0.90%	+411.96%	+495.33%	39.87B
IQVIA HOLDINGS INC.	-1.16%	+12.96%	+28.81%	+7.25%	38.68B
BEONE MEDICINES AG	-1.88%	-3.03%	+5.69%	+53.00%	35.13B
CELLTRION, INC.	-1.74%	+5.12%	+14.44%	+41.77%	29.79B
MEDPACE HOLDINGS, INC.	-0.21%	-4.04%	+36.40%	+125.75%	16.11B
ASCENDIS PHARMA A/S	-2.85%	-3.92%	-	-	16.08B
EUROFINS SCIENTIFIC SE	-0.64%	+2.65%	+3.40%	+13.11%	13.61B
ICON PUBLIC LIMITED COMPANY	-1.19%	-1.32%	-1.73%	-34.37%	12.62B
Average	-3.41%	-2.44%	+55.25%	+69.37%	25.04B
Weighted average by Cap.	-1.60%	+2.03%	+79.78%	+108.61%

	2024	2025
Net sales	8.5B 5.91M 5.14M 4.79M 4.39M 8.3M 565M 8.43M 56.41M 22.14M 281M 22.21M 21.73M 943M	2.01B 1.4M 1.21M 1.13M 1.04M 1.96M 133M 1.99M 13.32M 5.23M 66.38M 5.25M 5.13M 223M
Net income	-46.92B -32.65M -28.38M -26.42M -24.25M -45.8M -3.12B -46.51M -311M -122M -1.55B -123M -120M -5.2B	-11.77B -8.19M -7.12M -6.63M -6.08M -11.49M -782M -11.67M -78.11M -30.66M -389M -30.76M -30.08M -1.31B
Net Debt	29.34B 20.41M 17.74M 16.52M 15.16M 28.63M 1.95B 29.08M 195M 76.4M 970M 76.66M 74.97M 3.25B	3.79B 2.63M 2.29M 2.13M 1.96M 3.69M 251M 3.75M 25.12M 9.86M 125M 9.89M 9.67M 420M

3 years	4,245	63,000
5 years	4,245	145,500
10 years	4,245	261,500